IFNG and melanoma: Using a gene set of 6 members in the IFN-γ signaling pathway (IFNGR1, IFNGR2, JAK1, JAK2, STAT1, and IRF1), this group also mined the aforementioned 287 melanoma tissue samples and identified their mutations in 12.6% of them (36 cases), among which a decent fraction (44%, 16 of 36) had homozygous deletions in different genes, indicating a dysfunctional IFN-γ signaling.